2 terminated, 1 recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow SP-420: new trials by email Literature Review of SP-420 trials Research Report on SP-420
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes SP-420 - Beta Thalassemia Major Anemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | Pharmacosmos A/S | 90 | 2023-09-04 | 2025-09-24 |
| Safety of SP-420 in the Treatment of Transfusional Iron Overload SP-420 - Iron Overload | Phase 1 | Terminated | The University of Texas Health Science Center at San Antonio | 2 | 2021-03-09 | 2024-12-27 |
| SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias SP-420 - Iron Overload, Beta-Thalassemia | Phase 2 | Withdrawn | Abfero Pharmaceuticals, Inc | 2020-08-01 | 2020-10-05 | |
| Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia SP-420 - Iron Overload, Beta-Thalassemia | Phase 1 | Terminated | Sideris Pharmaceuticals | 24 | 2014-10-01 | 2015-09-29 |
Iron Overload (3) · beta-Thalassemia (2) · Myelodysplastic Syndromes (1) · Thalassemia (1)
Abfero Pharmaceuticals, Inc (1) · Pharmacosmos A/S (1) · Sideris Pharmaceuticals (1) · The University of Texas Health Science Center at San Antonio (1)
Canada (2) · Lebanon (2) · Thailand (2) · Turkey (Türkiye) (2) · United States (2) · Denmark (1)
Ali Taher, MD, PhD (1) · Supreet Kaur, MD (1)